KochiA. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle1991;72:1–6.
2.
ChretienJ. Tuberculosis and HIV. The cursed duet. Bull Union Int Tuberc Lung Dis1990;65(1):25–8.
3.
World Health Organization. Global Programme on AIDS: Current and Future Dimensions of the HIV/AIDS Pandemic-A Capsule Summary, WHO/GPA/RES/SFI/ 92.1. Geneva: WHO, 1992.
4.
FestensteinFGrangeJM. Tuberculosis and the acquired immune deficiency syndrome. J Appl Bacteriol1991;71:19–30.
5.
EtemadiAFaridRStanfordJL. Immunotherapy for drug-resistant tuberculosis. Lancet1992;340:1360–1.
6.
FriedenTRSterlingTPablos-MendezAKilburnJOCauthenGMDooleySW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med1993;328:521–6.
7.
FineP. Leprosy and tuberculosis - an epidemiological comparison. Tubercle1984;65:137–53.
8.
van der WerfTDadeGKvan der Mark. Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service programme. Tubercle1990;71:247–52.
9.
GirlingDJ. The chemotherapy of tuberculosis. In: RatledgeCStanfordJLGrangeJM, eds. The Biology of the Mycobacteria, Vol. 3. New York: Academic Press, 1989:284–323.
10.
GrangeJM. The mystery of the mycobacterial persistor. Tubercle Lung Dis1992;73:249–51.
11.
GibbsJHGrangeJMBeckJSJawadEPottsRCBothamleyGHEarly delayed-type hypersensitivity responses in tuberculin skin tests after heavy occupational exposure to tuberculosis. J Clin Pathol1991;44:919–23.
12.
SpringettV. Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle1971;52:73–87.
13.
MacAsseyLSaleebyCW, eds. Spahlinger Contra Tuberculosis 1908–1934. London: John Bale, Sons & Danielsson Ltd, 1934.
14.
FriedmannFF. Heil- und Schutzimpfung der menschlichen Tuberculose. Berl Klin Wschr1912;47:2214–7.
15.
MossmanTRMooreKW. The role of Il–10 in crossregulation of TH1 and TH2 responses. In: AshCGallagherRB, eds. Immunoparasitology Today. New York: Elsevier, 1991:A49–A53.
16.
RookGAWAl AttiyahR. Cytokines and the Koch phenomenon. Tubercle1991;72:13–20.
17.
StanfordJL. Koch's phenomenon: can it be corrected?Tubercle1991;72:241–9.
18.
GrangeJMGibsonJAOsbornTWCollinsCHYatesMD. What is BCG?Tubercle1983;64:129–39.
19.
GardnerLV. The history of the R1 strain of tubercle bacillus. Am Rev Tuberc1932;25:577–90.
20.
SavageWG. The Prevention of Human Tuberculosis of Bovine Origin. London: MacMillan, 1929.
21.
TripathySP. Fifteen year follow-up of the Indian BCG prevention trial. Proceedings of the 24th IVAT Conference on Tuberculosis Respiratory Disease. Singapore: Professional Postgraduate Services, 1987:69–72.
22.
StanfordJLShieldMJRookGAW. How environmental mycobacteria may predetermine the protective efficacy of BCG. Tubercle1981;62:55–62.
23.
FowlerWC. A preliminary report on the treatment of tuberculosis with turtle vaccine. Tubercle1930;12:12–7.
StanfordJLStanfordCAGhazi SaidiKDowlatiYWeissFFarshohiYVaccination and skin test studies on the children of leprosy patients. Int J Leprosy1989;57:38–44.
26.
StanfordJLBahrGMRookGAWShaabanMAChughTDGabrielMImmunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle1990;71:87–93.
27.
StanfordJLRookGAWBahrGMDowlatiYGanapatiRGhazi SaidiKMycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine1990;8:525–30.
28.
NyePMStanfordJLRookGAWLawtonPMacGregorMReilyCSuppressor determinants of mycobacteria and their potential relevance to leprosy. Lepr Rev1986;57:147–57.
29.
StanfordJLOmyebujohPCRookGAWGrangeJMPozniakA. Old plague, new plague, and a treatment for both?AIDS1993;7:1275–7.
30.
StanfordJLGrangeJMPozniakA. Is Africa Lost?Lancet1991;338:557–8.
31.
NarainJPRaviglioneMCKochiA. HIV-associated Tuberculosis in Developing Countries: Epidemiology and Strategies for Prevention, WHO/TB/92.164. Geneva: World Health Organization, 1992.
